TY - JOUR
T1 - From the prodromal stage of multiple sclerosis to disease prevention
AU - Marrie, Ruth Ann
AU - Allegretta, Mark
AU - Barcellos, Lisa F.
AU - Bebo, Bruce
AU - Calabresi, Peter A.
AU - Correale, Jorge
AU - Davis, Benjamin
AU - De Jager, Philip L.
AU - Gasperi, Christiane
AU - Greenbaum, Carla
AU - Helme, Anne
AU - Hemmer, Bernhard
AU - Kanellis, Pamela
AU - Kostich, Walter
AU - Landsman, Douglas
AU - Lebrun-Frenay, Christine
AU - Makhani, Naila
AU - Munger, Kassandra L.
AU - Okuda, Darin T.
AU - Ontaneda, Daniel
AU - Postuma, Ronald B.
AU - Quandt, Jacqueline A.
AU - Roman, Sharon
AU - Saidha, Shiv
AU - Sormani, Maria Pia
AU - Strum, Jon
AU - Valentine, Pamela
AU - Walton, Clare
AU - Zackowski, Kathleen M.
AU - Zhao, Yinshan
AU - Tremlett, Helen
N1 - Publisher Copyright:
© 2022, Springer Nature Limited.
PY - 2022/9
Y1 - 2022/9
N2 - A prodrome is an early set of signs or symptoms that indicate the onset of a disease before more typical symptoms develop. Prodromal stages are well recognized in some neurological and immune-mediated diseases such as Parkinson disease, schizophrenia, type 1 diabetes mellitus and rheumatoid arthritis. Emerging evidence indicates that a prodromal stage exists in multiple sclerosis (MS), raising the possibility of intervention at this stage to delay or prevent the development of classical MS. However, much remains unclear about the prodromal stage of MS and considerable research is needed to fully characterize the prodrome and develop standardized criteria to reliably identify individuals with prodromal MS who are at high risk of progressing to a diagnosis of MS. In this Roadmap, we draw on work in other diseases to propose a disease framework for MS that incorporates the prodromal stage, and set out key steps and considerations needed in future research to fully characterize the MS prodrome, identify early disease markers and develop standardized criteria that will enable reliable identification of individuals with prodromal MS, thereby facilitating trials of interventions to slow or stop progression beyond the prodrome.
AB - A prodrome is an early set of signs or symptoms that indicate the onset of a disease before more typical symptoms develop. Prodromal stages are well recognized in some neurological and immune-mediated diseases such as Parkinson disease, schizophrenia, type 1 diabetes mellitus and rheumatoid arthritis. Emerging evidence indicates that a prodromal stage exists in multiple sclerosis (MS), raising the possibility of intervention at this stage to delay or prevent the development of classical MS. However, much remains unclear about the prodromal stage of MS and considerable research is needed to fully characterize the prodrome and develop standardized criteria to reliably identify individuals with prodromal MS who are at high risk of progressing to a diagnosis of MS. In this Roadmap, we draw on work in other diseases to propose a disease framework for MS that incorporates the prodromal stage, and set out key steps and considerations needed in future research to fully characterize the MS prodrome, identify early disease markers and develop standardized criteria that will enable reliable identification of individuals with prodromal MS, thereby facilitating trials of interventions to slow or stop progression beyond the prodrome.
UR - http://www.scopus.com/inward/record.url?scp=85134356078&partnerID=8YFLogxK
U2 - 10.1038/s41582-022-00686-x
DO - 10.1038/s41582-022-00686-x
M3 - Article
C2 - 35840705
AN - SCOPUS:85134356078
SN - 1759-4758
VL - 18
SP - 559
EP - 572
JO - Nature Reviews Neurology
JF - Nature Reviews Neurology
IS - 9
ER -